Pure Global AI
NCT05984134Completed

Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction

Efficacy and Safety of Recombinant Human Thymosin β4(NL005) for Injection in Patients With Acute Myocardial Infarction: a Phase IIb Clinical Study
Beijing Northland Biotech. Co., Ltd.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Acute Myocardial Infarction
Drug/Device/Intervention
Middle Dose
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beijing Northland Biotech. Co., Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
Jul 15, 2022
End date
May 29, 2023
Enrollment
90 participants
Primary outcome

Percentage change of myocardial infarction area

Summary

A multicenter randomized double-blind placebo parallel control design was used in this study.
 The 90 participants were randomly assigned to placebo, 0.5μg/kg dose group, and 1.0μg/kg dose
 group in a ratio of 1:1:1. After randomization, subjects received the trial drug or placebo
 intravenously within 12 hours and on days 2 to 7 after PCI. The patients were observed 90
 days after PCI.

ICD-10 classifications
Acute myocardial infarctionAcute myocardial infarction, unspecifiedAcute subendocardial myocardial infarctionCertain current complications following acute myocardial infarctionOther current complications following acute myocardial infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05984134
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05984134 through Pure Global AI's free database. This Phase 2 trial is sponsored by Beijing Northland Biotech. Co., Ltd. and is currently Completed. The study focuses on Acute Myocardial Infarction. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.